by Beth Israel Deaconess Medical Center Credit: Pixabay/CC0 Public Domain In a recent phase 2b/3 clinical trial, a third mRNA vaccine against COVID-19—known as CVnCoV and developed by CureVac—reported approximately 48 percent efficacy against symptomatic disease. CV2CoV is a second generation vaccine developed by CureVac with noncoding modifications to optimize the vaccine. Researchers at Beth Israel...
by Walter Reed Army Institute of Research Credit: CC0 Public Domain Scientists from the Walter Reed Army Institute of Research and Naval Medical Research Center partnered with researchers at the University of Pennsylvania and Acuitas Therapeutics to develop a novel vaccine based on mRNA technology that protects against malaria in animal models, publishing their findings in...
AMERICAN CHEMICAL SOCIETY Messenger RNA (mRNA) vaccines to prevent COVID-19 have made headlines around the world recently, but scientists have also been working on mRNA vaccines to treat or prevent other diseases, including some forms of cancer. Now, researchers reporting in ACS’ Nano Lettershave developed a hydrogel that, when injected into mice with melanoma, slowly released...
